The journey of nanoparticles in the abdominal cavity: Exploring their in vivo fate and impact factors

IF 10.5 1区医学 Q1 CHEMISTRY, MULTIDISCIPLINARY Journal of Controlled Release Pub Date : 2024-10-16 DOI:10.1016/j.jconrel.2024.10.011

{"title":"The journey of nanoparticles in the abdominal cavity: Exploring their in vivo fate and impact factors","authors":"","doi":"10.1016/j.jconrel.2024.10.011","DOIUrl":null,"url":null,"abstract":"<div><div>Peritoneal carcinomatosis (PC) is caused by metastasis of primary tumor cells from intra-abdominal organs to the peritoneal surface. Intraperitoneal (IP) chemotherapy allows close contact of high concentrations of therapeutic agents with cancer cells in the peritoneal cavity to prolong patient survival. However, conventional IP chemotherapy is prone to rapid elimination from the peritoneal cavity and lacks specificity towards cancer cells. To address these challenges, there is an imperative demand for exploiting novel drug delivery systems to enhance drug retention in the peritoneal cavity and target PC cells. Therefore, in this review, we first recapitulate the physiological structures and barriers associated with IP drug delivery, highlighting the <em>in vivo</em> fate of nanoparticles (NPs) after IP administration. Furthermore, the influence of physicochemical properties (particle size, charge, surface modification, and carrier composition) on the <em>in vivo</em> fate of NPs is discussed. Perspectives on the rational design of NPs for IP therapy and recent clinical progress are also provided.</div></div>","PeriodicalId":15450,"journal":{"name":"Journal of Controlled Release","volume":null,"pages":null},"PeriodicalIF":10.5000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Controlled Release","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168365924006710","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Peritoneal carcinomatosis (PC) is caused by metastasis of primary tumor cells from intra-abdominal organs to the peritoneal surface. Intraperitoneal (IP) chemotherapy allows close contact of high concentrations of therapeutic agents with cancer cells in the peritoneal cavity to prolong patient survival. However, conventional IP chemotherapy is prone to rapid elimination from the peritoneal cavity and lacks specificity towards cancer cells. To address these challenges, there is an imperative demand for exploiting novel drug delivery systems to enhance drug retention in the peritoneal cavity and target PC cells. Therefore, in this review, we first recapitulate the physiological structures and barriers associated with IP drug delivery, highlighting the in vivo fate of nanoparticles (NPs) after IP administration. Furthermore, the influence of physicochemical properties (particle size, charge, surface modification, and carrier composition) on the in vivo fate of NPs is discussed. Perspectives on the rational design of NPs for IP therapy and recent clinical progress are also provided.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纳米粒子在腹腔中的旅程：探索其体内命运和影响因素。

腹膜癌（PC）是原发性肿瘤细胞从腹腔内器官转移到腹膜表面所致。腹膜内化疗可使高浓度的治疗药物与腹腔内的癌细胞密切接触，从而延长患者的生存期。然而，传统的腹腔内化疗容易从腹腔内迅速排出，而且对癌细胞缺乏特异性。为了应对这些挑战，人们迫切需要开发新型给药系统，以增强药物在腹腔内的滞留性并靶向 PC 细胞。因此，在这篇综述中，我们首先回顾了与 IP 给药相关的生理结构和障碍，强调了 IP 给药后纳米颗粒（NPs）在体内的命运。此外，我们还讨论了理化性质（粒度、电荷、表面修饰和载体成分）对 NPs 体内转归的影响。此外，还对用于 IP 治疗的 NPs 的合理设计和最新临床进展进行了展望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Controlled Release 医学-化学综合

CiteScore

18.50

自引率

5.60%

发文量

700

审稿时长

39 days

期刊介绍： The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.

期刊最新文献

Editorial Board Inside Back Cover Outside Front Cover Inside Front Cover The journey of nanoparticles in the abdominal cavity: Exploring their in vivo fate and impact factors